Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And when you think about the macro environment, where we are today, with a better understanding of interest rates, inflation, et cetera, we've seen a pretty strong demand for multifamily assets as we look across SOFR equity and our credit business |
| Last year, KREF's earnings potential benefited from the higher interest rate environment, with average run rate distributable earnings before losses of $0.48 per quarter throughout 2023 |
| We think obviously we've had a little bit of cyclicality as it relates to the equity markets but with where we are today and liquidity returning to the sector, I think we still feel very good about the intermediate and long-term prospects of the life science business |
| We feel very good about that component of the portfolio for those reasons |
| And overall, we feel like we're in a much better position today than a year ago with all that uncertainty |
| KREF is well-capitalized, with $136 million of cash, and $450 million of corporate revolver capacity available as of year-end, our best-in-class non-mark-to-market, and high levels of liquidity coupled with our deep relationships with both our financing partners and borrowers positions KREF strongly for this dynamic credit and interest rate environment |
| To put it simply, we have great real estate, we have ample liquidity and we have the resources and expertise to create value |
| Importantly, as we sell our REO portfolio, we can reinvest the capital into new loan assets to unlock additional earnings potential |
| Market sentiment has improved dramatically as some of the tail-risks driven by inflation and higher interest rates have subsided |
| It's better capital |
| As we continue to work through our watchlist portfolio we saw positive outcomes on two of our watches in D.C |
| We were happy to see the good news updates on those two D.C |
| So, that gives you a good roadmap for what we expect to happen there in the second quarter |
| Our capabilities have been further bolstered by our affiliated rated special servicer K-Star, with a team of more than 45 professionals and over $45 billion of special servicing rights, providing us with extensive expertise and access to sizable, real-time market information |
| To be clear, in the near-term, we expect DE ex-losses to be significantly higher than our dividend |
| Our financing continues to be best in class, which we further optimized by upsizing a repurchase agreement by $160 million, and extending the term |
| Access to KKR's broader real estate platform with approximately 150 dedicated professionals and over $68 billion of assets under management has been instrumental in the management of KREF's portfolio |
| I think that when we look at those, one, they are in very strong locations |
| But as we've talked about in the past, the rest of the office portfolio, we still feel good that we don't see any near-term intermediate-term migration of that portfolio into higher risk ratings |
| To be specific, we have built and maintained a market-leading liquidity position with the help of KKR Capital Markets, with current cash on hand and undrawn corporate revolver capacity of nearly $600 million |
| And we continue to see stable underlying performance across that segment with weighted average rent increases of 3.9% year-over-year in our portfolio |
| We're seeing a very large return in transaction volumes, both acquisitions and refinance |
| Before turning to the current market environment, company results, and dividend commentary, I'd like to highlight KREF's achievements during 2023 |
| I think what gives us the confidence, and we've highlighted this on other calls, is when you look at the three rated loans in the portfolio, they have very long lease terms in place, so over eight years of lease term in place |
| As Matt mentioned, our multifamily portfolio has generally been stable, with low single-digit rental increases supporting NOI growth |
| Of course, the goal is to gain more than that over time |
| So, you see equity investors in real estate trying to put money to work, and it's still a very good lending market just given the elevated rates and the lower basis you can lend on today |
| Our pipeline right now across all of our different pockets of capital is up over 50% from last year |
| Each has different circumstances, but this is high quality real estate that we have full confidence will lease and stabilize over time |
| It's safer |
| Statement |
|---|
| Distributable earnings this quarter were negative $26 million or negative $0.37 per share, including a write-off of $59 million or $0.85 per share |
| Third we downgraded the risk rating and increased reserves on a loan backed via Class A Seattle Life Sciences property |
| So, I think that's despite cash flow in some cases like there's clearly a very big deterioration there |
| But if we got into some type of like major cutting by the Fed, that will put pressure on the portfolio as well |
| First, upon taking title to the five-rated Philadelphia office asset we realized a $59 million loss, which is lower than the $69 million asset specific CECL reserve in the prior quarter |
| I think the Seattle Life Sciences is a good example of that where you are in the right sector, we are in a good property, leasing has slowed down, the business plan is very expensive to implement from our existing sponsors' perspective and that obviously is creating an issue in discussions with that loan |
| Today's higher interest rates and carrying costs combined with interest rate cap costs and near-term maturity dates continue to stress real estate capital structures |
| Book value per share as of December 31, 2023 was $15.52, a decline of approximately 5% quarter-over-quarter |
| The broader rally in equities and fixed income is impacting the commercial real estate equity of debt markets as well, with significant heightening in CMBS and loan spreads over the past few months |
| For the fourth quarter of 2023, we reported a GAAP net loss of $18.7 million or negative $0.27 per diluted share |
| So, a longwinded answer to your question, but we're not really anticipating that much trouble within the multifamily portfolio, but there'll be a little bit of noise here and there |
| There's still uncertainty |
| We think and our basis obviously, but we think we'll overcome potential issues there, but there's some uncertainty |
| Second, we increased reserves on our loans secured by the Class A office campus in Mountain View, California, reflecting a lower valuation given the continued slow leasing environment in Silicon Valley and the lower levels of liquidity |
| However, we downgraded two multifamily loans to risk ratings of 4 in the quarter given ongoing discussions regarding interest rate caps |
| Where you're seeing the most stress is in borrowers that have a little bit less liquidity, and so that interest rate cap becomes more problematic |
| And then, just going through the portfolio details, when I look life science specifically and I compare committed principal to current principal, many of the loans there's a substantial difference, which means there's a lot of future funding, which means these are not leased assets, these are development deals and there is very weak leasing in life science |
| And that's really the way we're thinking about it is, that's the portion of the portfolio that is not creating earnings, there is actually a drag around that from OpEx and something we have against those assets |
| You mentioned in your prepared remarks that it was mostly the earnings drag from REO assets and non-performing loans that really drove this decision to cut |
| And values have come down a lot |
Please consider a small donation if you think this website provides you with relevant information